uniQure (NASDAQ:QURE) Given New $9.00 Price Target at The Goldman Sachs Group

uniQure (NASDAQ:QURE) had its price objective lowered by The Goldman Sachs Group from $10.00 to $9.00 in a report released on Wednesday morning,Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the biotechnology company’s stock.

A number of other equities research analysts also recently commented on the company. Raymond James reaffirmed an “outperform” rating and issued a $20.00 price objective on shares of uniQure in a research report on Thursday, October 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $28.00 price objective on shares of uniQure in a research note on Wednesday. Royal Bank of Canada cut their price objective on shares of uniQure from $16.00 to $14.00 and set an “outperform” rating on the stock in a report on Wednesday. StockNews.com raised shares of uniQure to a “sell” rating in a research report on Thursday, October 17th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of uniQure in a research note on Tuesday, August 20th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $17.00.

uniQure Price Performance

NASDAQ:QURE opened at $7.79 on Wednesday. uniQure has a 12-month low of $3.73 and a 12-month high of $11.35. The firm has a market cap of $379.71 million, a price-to-earnings ratio of -1.57 and a beta of 0.90. The company’s 50-day moving average is $5.77 and its two-hundred day moving average is $5.83. The company has a current ratio of 6.51, a quick ratio of 7.36 and a debt-to-equity ratio of 0.92.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The business had revenue of $2.29 million for the quarter, compared to the consensus estimate of $2.73 million. Research analysts expect that uniQure will post -4.1 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. abrdn plc grew its stake in uniQure by 381.7% during the third quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after buying an additional 1,528,581 shares during the period. Vanguard Group Inc. boosted its position in uniQure by 11.4% during the 1st quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock worth $5,577,000 after purchasing an additional 109,740 shares during the period. Privium Fund Management B.V. increased its holdings in uniQure by 16.3% in the 3rd quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock valued at $3,672,000 after purchasing an additional 104,500 shares in the last quarter. BNP Paribas Financial Markets raised its position in uniQure by 4.3% in the first quarter. BNP Paribas Financial Markets now owns 736,724 shares of the biotechnology company’s stock valued at $3,831,000 after purchasing an additional 30,054 shares during the period. Finally, Acadian Asset Management LLC lifted its stake in shares of uniQure by 133.1% during the first quarter. Acadian Asset Management LLC now owns 613,490 shares of the biotechnology company’s stock worth $3,189,000 after purchasing an additional 350,291 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.